Strategy

            Joint R&D for potential BIC pipeline
          
            2017-12-28
          
            Building a leading edge in the clinical trial system
          
            Enhancing in-house R&D capabilities and Transforming to Global Innovation
          
            Integrate resources to strengthen commercialization capabilities

News

27 2023.10

BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China

08 2023.08

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

20 2023.07

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

21 2023.06

BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized, placebo-controlled Phase 2 clinical trial of its novel, oral endothelin A (ETA)-receptor selective antagonist, SC0062, with the enrollment of two patients with IgA nephropathy（IgAN）in China（NCT05687890）.

Career

We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.

Join Us